论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
单核细胞与高密度脂蛋白胆固醇比值对药物洗脱支架植入患者靶病变血管再通的预测价值
Authors Meng H, Zhou X, Li L, Liu Y, Liu Y, Zhang Y
Received 23 October 2024
Accepted for publication 1 February 2025
Published 7 March 2025 Volume 2025:18 Pages 1383—1391
DOI http://doi.org/10.2147/IJGM.S502386
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Yuriy Sirenko
He Meng,1,2 Xiujun Zhou,1,2 Lushan Li,1,2 Yuanying Liu,1,2 Yujie Liu,1,2 Ying Zhang1,2
1Department of Cardiology, Tianjin Chest Hospital, Tianjin, People’s Republic of China; 2Department of Cardiology, Chest Hospital, Tianjin University, Tianjin, People’s Republic of China
Correspondence: Ying Zhang; Yujie Liu, Email zhangying5020@163.com; liuyujie5020@163.com
Background: Severe in-stent restenosis (ISR) following the implantation of drug-eluting stent (DES) can lead to recurrent angina pectoris or even acute myocardial infarction, thereby necessitating target lesion revascularization (TLR). Prior studies have confirmed the correlation between the monocyte to high-density lipoprotein cholesterol ratio (MHR) and ISR after DES implantation. The potential of MHR to predict TLR following DES implantation remains an area of ongoing research and may have significant clinical implications.
Methods: A retrospective analysis was conducted on a consecutive series of 474 patients undergoing DES implantation and follow-up coronary angiography between December 1, 2014 and December 1, 2022. The patients were categorized into two distinct groups according to their exposure to TLR. To assess the predictive performance of the MHR with respect to TLR, we utilized multivariate logistic regression analysis and receiver operating characteristic (ROC) curve analysis.
Results: The study revealed a significant elevation in the MHR value within the TLR group compared to the non-TLR group (12.34 vs 8.97; P < 0.001). MHR was identified as an independent predictor of TLR (Odds Ratio [OR] = 1.162; 95% Confidence Interval [CI]: 1.102– 1.225). The area under the curve (AUC) was found to be 0.712 (95% CI: 0.664– 0.759). When the MHR exceeded 10.98, the specificity for predicting TLR was 75.8%, and the sensitivity was 58.0%. When the MHR was incorporated into the predictive model comprising established risk factors, there was a notable improvement in the AUC, from 0.689 to 0.749 (P < 0.001). Additionally, there was a significant categorical net reclassification improvement (NRI) of 0.183 (P < 0.001) and an integrated discrimination improvement (IDI) of 0.074 (P < 0.001).
Conclusion: The MHR functions as a predictor for TLR subsequent to DES implantation. Incorporating MHR into the predictive model improves the model’s accuracy, indicating its potential value for clinical application.
Keywords: monocyte to high density lipoprotein cholesterol ratio, target lesion revascularization, biomarker, inflammatory factors, lipid metabolism, drug-eluting stent